During your treatment with EPKINLY, we are here for you. MyNavCareTM is committed to helping patients like you gain access to information and support throughout your treatment.
With MyNavCare, you can receive personalized support throughout your treatment journey from a dedicated team that cares.
Your healthcare provider is your main source for treatment information. With MyNavCare, you gain access to additional resources and medication information.
MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:
Your Patient Engagement Liaison‡ is an experienced nurse and trained in treatment support. They’re dedicated to you, helping to:
*Based on eligibility requirements and Terms and Conditions.
†Eligibility criteria is determined by each independent third-party foundation. MyNavCare does not determine eligibility and cannot guarantee foundations will offer assistance.
‡Patient Engagement Liaisons are provided by MyNavCare Patient Support and do not work under the direction of your doctor or provide medical advice. Patients should speak with their doctor about any treatment-related questions.
If you are considering treatment with EPKINLY, use this guide to help you initiate a discussion with your doctor.
Once you've started EPKINLY, this guide will help you have a productive conversation with your doctor.
Keep track of how you are feeling and questions you have for your healthcare team.
You and your Care Partner should keep this card in the event a healthcare provider needs quick access to your important treatment-related information.
Here are some organizations that can help Patients and Care Partners connect with others, and provide information and resources throughout treatment.
There are many available resources that may be helpful to patients, families, and Care Partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.
Resources for your Care Partner can help them help you get the most from your treatment plan.
EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.
People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems.
Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.
EPKINLY can cause other serious side effects, including:
Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.
Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.
In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets.
In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells.
These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1‑855‑443‑6622).
Please see Medication Guide, including Important Warnings.
COM-US-EPK-0000771
